A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Diabetes Care

• Publication date

  2001-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.24.7.1226PMID 11423507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study.

  1999cited by this paper
• Thiazolidinediones: a new class of antidiabetic drugs

  1999influential reference
• Troglitazone has no effect on red cell mass or other erythropoietic parameters

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• Physicians' gender and clinical opinions of reproductive health matters.

  1998cited by this paper
• Epidemiologic aspects of lipid abnormalities.

  1998cited by this paper
• Type 2 diabetes mellitus: the grand overview

  1998cited by this paper
• The U.K. Prospective Diabetes Study: A review

  1998cited by this paper
• Troglitazone Reduces Plasma Leptin Concentration but Increases Hunger in NIDDM Patients

  1998cited by this paper
• Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

  1998cited by this paper
• UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years

  1998cited by this paper
• Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat

  1997cited by this paper
• NIDDM: a rapid progressive disease Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment

  1996cited by this paper
• Relation of Glycemic Control to Diabetic Microvascular Complications in Diabetes Mellitus

  1996cited by this paper
• Categorical Data Analysis Using The SAS1 System

  1995cited by this paper
• Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes

  1995cited by this paper
• Pathophysiology of insulin resistance in human disease.

  1995cited by this paper
• U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

  1995cited by this paper
• Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios

  1994cited by this paper
• Insulin resistance and insulin deficiency in the pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?

  1993cited by this paper
• Effects of insulin on renal sodium excretion.

  1992cited by this paper
• Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance

  1979cited by this paper
• Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

  1979cited by this paper

• Factors Affecting the Treatment Heterogeneity of PPARγ and Pan-PPAR Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Machine Learning-Based Meta-Regression Analysis

  2026cites this paper
• [Non-Insulin Antidiabetic Agents in the Management of Hyperglycaemia of Non-Critical Hospitalized Patients].

  2024cites this paper
• A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue.

  2024cites this paper
• The Modulatory Bioeffects of Pomegranate (Punica granatum L.) Polyphenols on Metabolic Disorders: Understanding Their Preventive Role against Metabolic Syndrome

  2023cites this paper
• 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.

  2022cites this paper
• A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control

  2021cites this paper
• Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy.

  2021cites this paper
• Are Insulin Sensitizers Useful Additions to Insulin Therapy?

  2021cites this paper
• Thiazolidinediones (TZDs)

  2021cites this paper
• Relation of cardiac function to insulin resistance as evaluated by hyperinsulinemic‐euglycemic clamp analysis in individuals with type 2 diabetes

  2021cites this paper
• Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets.

  2020cites this paper
• Japanese Clinical Practice Guideline for Diabetes 2019

  2020cites this paper
• Co-administration with Obestatin Reduces Accumulation of Subcutaneous Fat Due to Rosiglitazone Administration in DIO-C57BL/6 Mice

  2020cites this paper
• Japanese Clinical Practice Guideline for Diabetes 2019

  2020cites this paper
• Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus

  2020cites this paper
• A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe.

  2020cites this paper
• Co-administration with Obestatin Reduces Accumulation of Subcutaneous Fat Due to Rosiglitazone Administration in DIO-C57BL/6 Mice

  2020cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Thérapeutique des désordres glycémiques

  2019cites this paper
• Heart Failure in Type 2 Diabetes Mellitus.

  2019cites this paper
• Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis

  2019cites this paper
• A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.

  2019cites this paper
• Japanese Clinical Practice Guideline for Diabetes 2016

  2018cites this paper
• Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review

  2018cites this paper
• Effect of glucose-lowering therapies on heart failure

  2018cites this paper
• Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

  2018influential citation
• Japanese Clinical Practice Guideline for Diabetes 2016

  2018cites this paper
• Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis

  2018cites this paper
• LOWER DAILY DOSE WITH BETTER OUTCOMES WITH ORAL AGENTS AND AM INSULIN TOUJEO ADMINISTRATION THAN LANTUS WHILE ATTAINING DESIRABLE GLYCEMIC CONTROL IN TYPE 2 DIABETES

  2018cites this paper
• The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus

  2018cites this paper
• A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

  2018cites this paper
• Medications that cause weight gain and alternatives in Canada: a narrative review

  2018cites this paper
• Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice

  2018cites this paper
• Effect of Hexadecyl Azelaoyl Phosphatidylcholine on Cardiomyocyte Apoptosis in Myocardial Ischemia-Reperfusion Injury: A Hypothesis

  2018cites this paper
• Immense Insulin Intestinal Uptake and Lymphatic Transport Using Bile Acid Conjugated Partially Uncapped Liposome.

  2018cites this paper
• Hexane extract of raw ginger enhances adipocyte differentiation through its PPARγ ligand activity on 3T3-L1 preadipocytes

  2017cites this paper
• On girls ‘ dying of diabetes-1 ’ : not those registered with TAG-VHS

  2017cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2017cites this paper
• Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis

  2017cites this paper
• Effects of Rosiglitazone and Metformin as monotherapy and in combination on high fructose diet induced hyperglycemia and dyslipidaemia in rats

  2017cites this paper
• Treatment Strategies for Type 2 Diabetes Based on Incretin Action

  2016cites this paper
• Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

  2016cites this paper
• PPARγ signaling and emerging opportunities for improved therapeutics.

  2016cites this paper
• Cardiovascular safety of anti-diabetic drugs.

  2016cites this paper
• Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes

  2016cites this paper
• Heart failure in diabetes: effects of anti-hyperglycemic drug therapy

  2016cites this paper
• Β-CELL FAILURE AND PRESERVATION IN TYPE 2 DIABETES MELLITUS: A REVIEW

  2016cites this paper
• Combination Tratment of Oral Agents and Insulin in Type 2 Diabetes: A Narrative Review

  2016cites this paper
• Retrospective Observational Dose-Titration Study of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on 15 mg of Pioglitazone

  2016cites this paper
• Evidence-based practice guideline for the treatment for diabetes in Japan 2013

  2015cites this paper
• Insulin Use and Risk of Diabetic Macular Edema in Diabetes Mellitus: A Systemic Review and Meta-Analysis of Observational Studies

  2015cites this paper
• Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.

  2015cites this paper
• Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

  2015cites this paper
• A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

  2015cites this paper
• Drug interactions are an important issue in type 2 diabetes

  2015influential citation
• Pharmacologic Approach to Type 2 Diabetes in Obese Patients

  2015cites this paper
• Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.

  2015cites this paper
• Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes

  2015cites this paper
• Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population.

  2015cites this paper
• Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention

  2015cites this paper
• PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.

  2015cites this paper
• Original Article Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis

  2015cites this paper
• Drug interactions are an important issue in type 2 diabetes

  2015influential citation
• APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome

  2014cites this paper
• Chapitre 7 – Thérapeutique des désordres glycémiques

  2014cites this paper
• Insulin therapy in type 2 diabetes : Initiation, impact on liver fat, role of combination therapy with glitazones or glindes

  2014cites this paper
• Human in vivo studies on the non-glycaemic effects of thiazolidinedione derivatives

  2014cites this paper
• Part of the Special Issue: Metabolism 2014 - Alterations of metabolic pathways as therapeutic targets Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARg): a review

  2014cites this paper
• The impact of an 8-week green-exercise programme on systemic health, and on markers associated with cardiovascular disease risk

  2014cites this paper
• Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review

  2014cites this paper
• Novel effects of rosiglitazone on SMAD2 and SMAD3 signaling in white adipose tissue of diabetic rats

  2014cites this paper
• Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with Rosiglitazone

  2014cites this paper
• Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions

  2014influential citation
• Management of Type 2 diabetes mellitus in primary care

  2014cites this paper
• Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?

  2013cites this paper
• Complementing Insulin Therapy to Achieve Glycemic Control

  2013cites this paper
• Pleiotropic Effects of Thiazolidinediones: Implications for the Treatment of Patients With Type 2 Diabetes Mellitus

  2013cites this paper
• Pharmacological modulation of insulin resistance : benefits and harms

  2013cites this paper
• In Vivo Actions of Peroxisome Proliferator–Activated Receptors

  2013cites this paper
• The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes

  2013cites this paper
• Efficacy of Pioglitazone as a Monotherapy on Glycemic Control, Lipids and Blood Pressure in Patients with Type 2 Diabetes Mellitus

  2013cites this paper
• Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?

  2013cites this paper
• Pharmacologic management of type 2 diabetes.

  2013cites this paper
• Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity

  2013cites this paper
• Treatment with thiazolidinediones

  2013cites this paper
• Plakilactones from the marine sponge Plakinastrella mamillaris. Discovery of a new class of marine ligands of peroxisome proliferator-activated receptor γ.

  2012cites this paper
• Rosiglitazone

  2012cites this paper
• Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.

  2012cites this paper
• Metabolic and Additional Vascular Effects of Thiazolidinediones

  2012cites this paper
• Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.

  2012cites this paper
• Effect of Thiazolidinediones (Glitazones) groups on Glycemic control and Lipid profile: A Meta-analysis of Randomized Control Trials

  2012cites this paper
• [Surrogate outcomes].

  2012cites this paper
• Highlights from the latest articles in diabetes pharmacogenomics.

  2012cites this paper
• A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study.

  2012cites this paper
• Current Management Strategies for Coexisting Diabetes Mellitus and Obesity

  2012cites this paper
• Thiazolidinediones in Type 2 Diabetes Mellitus

  2012cites this paper
• Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion.

  2012cites this paper
• Bundesärztekammer Kassenärztliche Bundesvereinigung Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften

  2011cites this paper
• FEASIBILITY OF ROSIGLITAZONE MALEATE FOR TRANSDERMAL DELIVERY

  2011cites this paper
• Advances in the treatment of type 2 diabetes mellitus.

  2011cites this paper